Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus.
OBJECTIVE
To investigate the role of the anti-cellular immune response in the protection of rhesus macaques against infection with the simian immunodeficiency virus SIVmac. To determine the biological differences between SIV challenge stocks grown either on human T-cell lines or on monkey peripheral blood mononuclear cells (MPBMC).


METHODS
A protective SIVmac split vaccine was administered to rhesus macaques and their anti-, B- and T-cell response monitored. Vaccinees and controls were challenged with SIVmac grown either on human or on monkey cells. The in vivo replication rate of, and the immune response to, the two viruses was compared.


METHODS
Five rhesus macaques were immunized with a total of 2 mg each of purified SIVmac251/32H grown on the human C8166 T-cell line. The antibody and proliferative T-cell responses were evaluated by enzyme-linked immunosorbent assay and T-cell proliferation assay, respectively. Four protected animals and four controls were reboosted and challenged with MPBMC-grown SIVmac251 (SIVmac251/MPBMC). Cell-free virus load was determined by titration of plasma for SIV infectivity on C8166 cells and antigen with a core antigen capture assay.


RESULTS
Protection from virus challenge with C8166-grown SIVmac251/32H or SIVmac251/MPBMC did not correlate with anti-cellular antibodies or proliferative T-cell reactivities. Control animals infected with SIVmac251/MPBMC showed high persistent antigenaemia and high plasma virus titres. Both were absent in controls infected with complement C8166-grown SIVmac251/32H. Whereas the latter always seroconverted against the full panel of viral polypeptides, SIVmac251/MPBMC-infected animals showed a drastically decreased antibody response.


CONCLUSIONS
Neither the antibody nor the proliferative T-cell response to SIVmac correlates with protection from virus challenge. In contrast to SIVmac251/32H grown on C8166 cells, the MPBMC-grown challenge virus SIVmac251 appears to belong to the 'rapid-high' phenotype, possibly explaining the lack of protection against this SIV.
Stahl-Hennig
C
C
Deutsches Primatenzentrum, Abteilung Virologie und Immunologie, Göttingen, Germany.
Voss
G
G
Dittmer
U
U
Coulibaly
C
C
Petry
H
H
Makoschey
B
B
Cranage
M P
MP
Aubertin
A M
AM
Lüke
W
W
Hunsmann
G
G
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D000956:Antigens, Viral / Q000097:blood; D002460:Cell Line; D002478:Cells, Cultured; D004279:DNA, Viral / Q000097:blood; D015686:Gene Products, env / Q000276:immunology*; D007117:Immunization, Secondary; D007963:Leukocytes, Mononuclear / Q000382:microbiology; D008213:Lymphocyte Activation; D008253:Macaca mulatta / Q000276:immunology*; D011533:Proviruses / Q000302:isolation & purification; D015682:Retroviridae Proteins, Oncogenic / Q000276:immunology*; D015302:Simian Immunodeficiency Virus / Q000254:growth & development / Q000276:immunology* / Q000472:pathogenicity; D013045:Species Specificity; D013601:T-Lymphocytes / Q000382:microbiology; D014760:Viral Fusion Proteins; D014765:Viral Vaccines / Q000276:immunology*; D014774:Virulence; D014776:Virus Cultivation; D014779:Virus Replication
D000914:Antibodies, Viral; D000956:Antigens, Viral; D004279:DNA, Viral; D015686:Gene Products, env; D015682:Retroviridae Proteins, Oncogenic; D014760:Viral Fusion Proteins; D014765:Viral Vaccines; C059580:transmembrane protein, Simian immunodeficiency virus